JanOne (NASDAQ: JAN) is Trending as Its Lead Product for Pain Advances in Clinical Trials

JanOne (NASDAQ: JAN) is Trending as Its Lead Product for Pain Advances in Clinical Trials

Following today’s volume and price action, could JAN have a short position that exceeds the 2.38M shares in the float? One Redditor thinks so… https://www.reddit.com/r/Shortsqueeze/comments/o5rj99/does_jan_have_100_short_interest_now/

Good day everyone,

Join our “Breakout Stocks” group on Reddit

We are initiating coverage on JanOne (NASDAQ: JAN) today. This one seems to be just starting to trend as 12% of the tiny 2.38M share float is currently sold short. This doesn’t make a lot of sense to us as Jan is advancing clinical trials and has non-dilutive cash on hand from the sale of their legacy business.

Current price $8.50 per share
Outstanding shares (est.) 2.82M
Float (est.) 2.38M
Insider ownership 29.26%
Market cap $25.2M
Revenues $34M

A Few of Our Favorite Highlights:

Cash on hand to fund operations.
A very tiny share structure.
High insider/institutional ownership.

Note that there is around 12% of the float currently sold short.

All the indications point toward a potential near term upswing in JAN shares. They are trending and the company is producing potential catalysts relating to product development.

The company’s lead product is JAN101, a patented sustained-release form of FDA approved sodium nitrite. Results from the recently completed Phase 2a clinical trials support the use of sodium nitrite for the treatment and prevention of Peripheral Artery Disease (PAD), and as a non-addictive treatment for Diabetic Neuropathy.

When we look at the company stock chart, we notice a few things. The shares have recently broken through their 50 and 200 DMA of $7.44 and $6.30 respectively, in a bullish manner. The simple Moving Average is green at all levels.

Investors are taking a positive stance on the company shares which seem to be trending. The implications for JAN101, beyond the treatment of PAD, the subject of the phase 2a trial, are becoming more evident and the company has taken steps to facilitate a phase 2b trial and beyond.

200,000 doses of JAN101, including placebo have already been manufactured. The initial batch was produced by manufacturing partner CoreRX. According to Tony Isaac, President and Chief Executive Officer of JanOne, “We are now focused on bottling and labeling JAN101 for distribution to clinical test sites and engaging a contract research organization (CRO) to manage our Phase 2b trial, including the recruitment of subjects.”

The proposed phase 2b clinical trial of JAN101:

Evaluate the efficacy of two doses (40 mg and 80 mg) of JAN101 to treat diabetic patients with PAD in a placebo-controlled, 12-week study.

300 diabetic PAD adults (≥18 years) – 3 cohort of 100 patients

Primary endpoint
• Ability to walk without pain or muscle fatigue because of restored vascular function.

Secondary endpoints
• Reduction in pain over course of treatment
• Improved sensory nerve function
• Improved quality of life

The company has stated that the onset of the phase 2b trial could start at any time.

JAN has engaged the services of DC Consulting LLC, a strategy and management consulting firm specializing in government affairs, regulatory guidance, marketing strategy, and public relations services relating to healthcare, pharmaceuticals, drug policy and prevention, law enforcement, and building healthy communities.

Other potential indications for JAN101 include diabetic neuropathy, wound healing, and vascular inflammation by alleviating disease-associated pain at the source, and we believe investors are interested in JAN101 for its potential, not only for PAD, but its potential impact on other indications.

JAN is also exploring JAN101 as an alternative pain reliever to opioids. The FDA approval for pain relief would be a significant catalyst for the company’s value.

Recent injection of non-dilutive capital
In February, the company sold its legacy recycling subsidiary, ARCA Recycling for approximately $25M. That move initiated a temporary (few days) spike in the company share price that peaked at $31.93/share. We discount the importance of that spike as it was caused by a one time event unrelated to the operations of its core biopharma business.

Stay tuned and stay informed,
The Traders News Group


Privacy Policy and Disclaimer
Your Consent
By using our site, you consent to our online privacy policy and disclaimer.
Do we disclose any information to outside parties?
We do not sell your information to anyone. Please see our cookie policy below.
What information do we collect?
We collect information from you when you subscribe to our newsletter or fill out a form on one of our social platforms. This includes your email address and or mobile phone number.
When registering on our site, as appropriate, you may be asked to enter your: e-mail address and or mobile number.
What do we use your information for?
When we collect your email or mobile number it is used for one purpose to send you the information you requested about small cap stocks. Please read our disclaimer carefully before viewing our emails.
Your information, whether public or private, will not be sold, exchanged, transferred, or given to any other company for any reason whatsoever, other than for the express purpose of delivering the information on small cap stocks that you requested.
We send periodic emails
The email address you provide may be used to send you information, the small acp stock reports you requested, respond to inquiries, and/or other requests or questions.
How do we protect your information?
We implement a variety of security measures to maintain the safety of your personal information when you enter, submit, your email address. We use secure third parties to send email and sms messages to you.
Because we value your privacy we have taken the necessary precautions to be in compliance with the California Online Privacy Protection Act.
Online Privacy Policy Policy
This online privacy policy applies to information collected through our website and social media platforms.
Contacting Us
If there are any questions regarding this privacy policy or disclaimer you may contact us using the information below.
Traders News Source is a wholly owned subsidiary of Traders News Source LLC, herein referred to as TNS LLC.
Our reports/releases are a commercial advertisement and are for general information purposes ONLY. We are engaged in the business of marketing and advertising companies for monetary compensation. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. The disclaimer is to be read and fully understood before using our services, joining our site or our email/blog list as well as any social networking platforms we may use.

Please Note: TNS LLC and its employees are not a registered investment advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever.

Release of Liability: Through use of this website viewing or using you agree to hold TNS LLC, its operators owners and employees harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damage (monetary or otherwise), or injury (monetary or otherwise) that you may incur. The information contained herein is based on sources which we believe to be reliable but is not guaranteed by us as being accurate and does not purport to be a complete statement or summary of the available data. TNS LLC encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and TNS LLC makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies. None of the materials or advertisements herein constitute offers or solicitations to purchase or sell securities of the companies profiled herein and any decision to invest in any such company or other financial decisions should not be made based upon the information provide herein. Instead TNS LLC strongly urges you conduct a complete and independent investigation of the respective companies and consideration of all pertinent risks. Readers are advised to review SEC periodic reports: Forms 10-Q, 10K, Form 8-K, insider reports, Forms 3, 4, 5 Schedule 13D. TNS LLC is compliant with the Can Spam Act of 2003. TNS LLC does not offer such advice or analysis, and TNS LLC further urges you to consult your own independent tax, business, financial and investment advisors. Investing in micro-cap and growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investors investment may be lost or impaired due to the speculative nature of the companies profiled.
The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements indicating certain actions & quote; may, could, or might occur. Understand there is no guarantee past performance will be indicative of future results.
In preparing this publication, TNS LLC has relied upon information supplied by its customers, publicly available information and press releases which it believes to be reliable; however, such reliability cannot be guaranteed. Investors should not rely on the information contained in this website. Rather, investors should use the information contained in this website as a starting point for doing additional independent research on the featured companies. The owners and operators of this website were previously compensated twenty one thousand dollars cash via bank wire for our distributed opinions on ctxr, however we have not been compensated for this particular mention of ctxr. The advertisements in this website are believed to be reliable, however, TNS LLC and its owners, affiliates, subsidiaries, officers, directors, representatives and agents disclaim any liability as to the completeness or accuracy of the information contained in any advertisement and for any omissions of materials facts from such advertisement. TNS LLC is not responsible for any claims made by the companies advertised herein, nor is TNS LLC responsible for any other promotional firm, its program or its structure.
TNS LLC is not affiliated with any exchange, electronic quotation system, the Securities Exchange Commission or FINRA. TNS LLC is not a Broker/Dealer and does not engage in high frequency trading.